Drug Information

Drug (ID: DG01156) and It's Reported Resistant Information

• Name: Rifamycin
• Synonyms: RIFAMYCIN; Rifamycin SV; Rifocin; Rifamicine SV; Rifomycin SV; Rifamicina; Rifamycine; Rifamycinum; Rifocyn; 6998-60-3; CB-01-11; UNII-DU69T8ZZPA; DU69T8ZZPA; CHEBI:29673; 6998-60-3 (free acid); M-14; Aemcolo; Rifamycine [INN-French]; Rifamycinum [INN-Latin]; Rifamicina [INN-Spanish]; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; RIFOMYCIN; C37H47NO12; 15105-92-7; EINECS 230-273-3; Tuborin; rifamycin-sv; NSC133100; Rifamycin [USAN:INN:BAN:DCF]; Rifamycin (USAN/INN); SCHEMBL151824; CHEMBL437765; GTPL4570; DTXSID1032014; 8248AH; BDBM50391000; LMPK05000005; AKOS024281286; ZINC169633673; DB11753; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate; Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other means; D02549; SR-01000872597; SR-01000872597-1; (pentahydroxy-methoxy-heptamethyl-dioxo-[ ]yl) acetate; Q26270990; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; (7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate; (7S,11S,13S,17S,18S,12R,14R,15R,16R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate; 2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,16S,17S,18R,19R,20R,21S,22R,23S)-
• Indication:
  In total 2 Indication(s)
  Diarrhea [ICD-11: DA90]; Approved; [1]
  Infectious disease [ICD-11: 1A00-CA43]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Bacterial infection [ICD-11: 1A00-1C4Z]; [1]
• Target: Bacterial RNA polymerase sigma factor SigA (Bact sigA); SIGA_STAA8; [1]
• Target: Mycobacterium RNA polymerase (MycB RNAP); RPOA_MYCTU RPOB_MYCTU RPOC_MYCTU RPOZ_MYCTU; [1]
• Target: Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB); RPOB_STAA8; [1]
• Formula: C37H47NO12
• IsoSMILES: C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C
• InChI: 1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
• InChIKey: HJYYPODYNSCCOU-ODRIEIDWSA-N
• PubChem CID: 6324616
• ChEBI ID: CHEBI:29673
• TTD Drug ID: D0FX2Q
• VARIDT ID: DR00614
• DrugBank ID: DB11753

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Bacterial infection [ICD-11: 1A00-1C4Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Ribonucleic Acid Polymerase (RNAP) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Mycobacterium abscessus infection [ICD-11: 1A00-1C4Z]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SOSP-9607 cells; Bones; Homo sapiens (Human); CVCL_4V80
• Experiment for Molecule Alteration: In vitro rifampicin ADP-ribosyl transferase activity assay; Rifampicin ADP-ribosyl transferase disk assay; Rifampicin ADP-ribosyl transferase MIC assay
• Mechanism Description: Rifamycin resistance is usually associated with mutations in RNAP that preclude rifamycin binding.

References

• Ref 1: Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein .Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0086421. doi: 10.1128/AAC.00864-21. Epub 2021 Oct 4. 10.1128/AAC.00864-21